Availability
0
Your Basket is Empty
BB164258
BIO-X

Bortezomib

Selective and reversible inhibitor of the multicatalytic 26S proteasome. The inhibition of protein breakdown affects several metabolic pathways and leads to cell death. The compound is effective in treating multiple myeloma because it prevents the binding of myeloma cells to bone marrow stroma and inhibits osteoclast differentiation.

Technical Data

CAS No: 179324-69-7
Synonyms: [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid; Velcade; Radiciol
Product Code: BB164258
MDL No: MFCD09056737
Chemical Formula: C19H25BN4O4
Molecular Weight: 384.24

References


  • Curran and McKeage (2009). Bortezomib. 69(7):859-888.
  • Metzler et al (2007). Bortezomib inhibits human osteoclastogenesis. Leukemia 21:2025-2034.

Solubility

Stability

Further Information


Datasheets

Specification: View
MSDS: View

CAS No:
179324-69-7
Synonyms:
[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid
Velcade
Radiciol
MDL No:
MFCD09056737
Chemical Formula:
Molecular Weight:
384.24
Product Structure
References:
1. Curran and McKeage (2009). Bortezomib. 69(7):859-888.
2. Metzler et al (2007). Bortezomib inhibits human osteoclastogenesis. Leukemia 21:2025-2034.
Click for Specification
Click for MSDS

For requirements greater than the catalogue prepacks email: enquiries@carbosynth.com

Custom Synthesis

For custom synthesis or special requests email: enquiries@carbosynth.com, call +44 (0)1635 578444 or fill out our contact form

Please Wait...